• Type:
  • Category:

Genomtec SA: Investor Relations & Financial Insights | seat11a

red bg - Genomtec SA: Investor Relations & Financial Insights | seat11a -%sitename%

Genomtec S.A. Investor Relations:
Your Hub for Financial Insights and Updates

Quick Video Briefs

mobile 16 9 - Genomtec SA: Investor Relations & Financial Insights | seat11a -%sitename%
Vimeo

By loading the video, you agree to our Terms & Conditions,
our Privacy Policy and Vimeo's privacy policy.

Load video

Genomtec S.A.

Bierutowska 57-59, Budynek 3A

51-317 Wrocław, Poland

Genomtec is an innovative medical technology company dedicated to the development and commercialization of Genomtec®ID – a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

red bg - Genomtec SA: Investor Relations & Financial Insights | seat11a -%sitename%
line 1 - Genomtec SA: Investor Relations & Financial Insights | seat11a -%sitename%
Genomtec S.A.

Video Hub

line 2 - Genomtec SA: Investor Relations & Financial Insights | seat11a -%sitename%
red bg - Genomtec SA: Investor Relations & Financial Insights | seat11a -%sitename%
line 1 - Genomtec SA: Investor Relations & Financial Insights | seat11a -%sitename%
Genomtec S.A.

At a Glance

line 2 - Genomtec SA: Investor Relations & Financial Insights | seat11a -%sitename%

Introduction to Genomtec and Genomtec®ID

Genomtec is an innovative medical technology company dedicated to the development and commercialization of Genomtec®ID – a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.


Genomtec®ID: A Pioneering Mobile IVD Platform

The company’s flagship project is the Genomtec®ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.


Development and Manufacturing Process

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies.


Commercialization of Genomtec®ID

According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution Genomtec®ID will take place in the first half of 2022.


Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® Laboratory Tests

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.


About Genomtec

Genomtec was founded in 2016 and it is headquartered in Wroclaw. More information at: genomtec.com.

(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

Elevate your understanding with powerful Elevator Pitches, Deep-Dive Presentations, and in-depth Financial Analysis

Scroll to top